Discover
FDMT
4D Molecular Therapeutics, Inc.
12.19
1 x 8.88
1 x 13.56
bid
ask
+
0.54
4.64%
undefined @ 04:00 PM
12.19 +0.00 (0.00%)
| Ytd | 62.53% | |
| 1y | 71.69% |
11.27
day range
12.35
6.14
52 week range
13.30
| Open | 11.48 | Prev Close | 11.65 | Low | 11.27 | High | 12.35 | Mkt Cap | 637.25M |
| Vol | 773.74K | Avg Vol | 844.38K | EPS | -2.57 | P/E | -4.74 | Forward P/E | -1.79 |
| Beta | 2.73 | Short Ratio | 9.86 | Inst. Own | 115.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 10.81 | 200-d Avg | 9.79 | 1yr Est | 42.64 |
FDMT News
globenewswire.com
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT
zacks.com
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line wit
globenewswire.com
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Mil
Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4
benzinga.com
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price
B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDA
benzinga.com
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to
benzinga.com
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM
benzinga.com
Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with c